Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) PT at $74.86

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has been given a consensus recommendation of “Buy” by the nine ratings firms that are presently covering the firm, MarketBeat reports. Nine equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $74.86.

JSPR has been the topic of a number of research analyst reports. JMP Securities reaffirmed a “market outperform” rating and issued a $70.00 target price on shares of Jasper Therapeutics in a report on Tuesday, October 15th. Royal Bank of Canada cut their price target on shares of Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating on the stock in a report on Wednesday, August 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Jasper Therapeutics in a research note on Monday, September 9th. HC Wainwright reaffirmed a “buy” rating and issued a $65.00 price target on shares of Jasper Therapeutics in a research note on Thursday, October 24th. Finally, Evercore ISI reiterated an “outperform” rating and issued a $65.00 target price on shares of Jasper Therapeutics in a report on Monday, August 26th.

Institutional Trading of Jasper Therapeutics

Several hedge funds have recently made changes to their positions in the company. Braidwell LP bought a new position in Jasper Therapeutics in the 3rd quarter valued at $9,091,000. Ally Bridge Group NY LLC boosted its position in Jasper Therapeutics by 82.7% during the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock valued at $7,514,000 after buying an additional 180,852 shares during the period. StemPoint Capital LP bought a new stake in Jasper Therapeutics in the 1st quarter worth $3,794,000. Ikarian Capital LLC bought a new stake in shares of Jasper Therapeutics in the first quarter worth about $3,088,000. Finally, Russell Investments Group Ltd. bought a new position in shares of Jasper Therapeutics during the first quarter valued at approximately $2,343,000. 79.85% of the stock is currently owned by institutional investors.

Jasper Therapeutics Price Performance

Shares of JSPR stock opened at $22.10 on Tuesday. Jasper Therapeutics has a one year low of $4.00 and a one year high of $31.01. The company has a fifty day moving average price of $20.21 and a two-hundred day moving average price of $20.97. The stock has a market cap of $333.71 million, a P/E ratio of -4.66 and a beta of 2.19.

Jasper Therapeutics (NASDAQ:JSPR) last announced its earnings results on Tuesday, August 13th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.09) by $0.12. As a group, equities research analysts anticipate that Jasper Therapeutics will post -4.47 EPS for the current fiscal year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.